Subjects will be screened within 30 days prior to randomization. Randomization will be stratified according to whether the subject ever received prior influenza vaccination. Approximately 50% of the subjects will not have been previously vaccinated. All subjects will receive two doses of investigational product on Study Days 1 and 28, and followed for a 28-day follow-up period after each dose. Blood and nasal samples will be collected and safety evaluations perfomed.